Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

19 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Alexion Pharmaceuticals Articles

News briefs: Grunenthal adds to portfolio; Ajinomoto to buy Althea; Alexion's Soliris OKed in Canada

6 March 2013

Alexion tells shareholders to reject TRC's unsolicited mini-tender offer

7 February 2013

ASN meeting highlights Otsuka's tolvaptan' Alexion's Solaris and Roche's aleglitazar research

5 November 2012

EMA orphan drug committee makes 16 recommendations at May meeting

28 May 2012

Alexion to buy Enobia Pharma for potential $1 billion

30 December 2011

FDA approves Alexion’s Soliris for rare pediatric blood disorder and J&J’s Remicade for children with UC

25 September 2011

Alexion acquires Taligen Therapeutics for $111 million

2 February 2011

Australia’s fight against cancer continues with new additions to the PBS, says health minister

10 December 2010

Showing 1-8 of 8 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Neovacs moving forward in rheumatoid arthritis, say analysts
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Neovacs moving forward in rheumatoid arthritis, say analysts

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS